Cellay

Executive Summary

Cellay, Inc. is a Cambridge-based biotechnology company specializing in rapid fluorescence in situ hybridization (FISH) probes. Founded in 2018, its proprietary Same Day OligoFISH® Probes drastically reduce hybridization time from hours or days to minutes, enabling faster chromosomal analysis for research and diagnostic applications in cytogenetics and cell therapy. This technology addresses a critical bottleneck in genomic analysis, offering potential improvements in turnaround time for clinical decisions and cell therapy quality control. As a private company with no disclosed funding, Cellay operates in a niche but growing market, leveraging its speed advantage to differentiate from traditional FISH providers. The company's focus on cell therapy aligns with a rapidly expanding sector, positioning it for strategic partnerships or licensing deals. However, limited publicly available information on revenue, stage, or competitive landscape tempers conviction. Overall, Cellay presents a compelling innovation with clear value proposition, but execution and market adoption remain to be demonstrated.

Upcoming Catalysts (preview)

• Q4 2026Regulatory clearance for diagnostic use of Same Day OligoFISH® Probes55% success
• Q2 2027Strategic partnership with a cell therapy manufacturer60% success
• Q3 2026Completion of Series A funding round70% success